Table of Content
1. Report Prologue
2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary research
3.4 Market Size Estimation
4. Market Dynamics
4.1 Drivers
4.2 Restrains
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
6. Global Diabetic Nephropathy Market, by Diagnosis
6.1 Introduction
6.2 Urine Test
6.2.1 Market Estimates & Forecast, 2020-2027
6.3 Blood Test
6.3.1 Market Estimates & Forecast, 2020-2027
6.4 Imaging tests
6.4.1 Market Estimates & Forecast, 2020-2027
6.5 Renal function testing
6.5.1 Market Estimates & Forecast, 2020-2027
6.6 Kidney biopsy
6.6.1 Market Estimates & Forecast, 2020-2027
7. Global Diabetic Nephropathy Market, by Treatment
7.1 Introduction
7.2 Medications
7.2.1 Market Estimates & Forecast, 2020-2027
7.3 Kidney Dialysis
7.3.1 Market Estimates & Forecast, 2020-2027
7.4 Transplant
7.4.1 Market Estimates & Forecast, 2020-2027
8. Global Diabetic Nephropathy Market, by Indication
8.1 Introduction
8.2 Diabetes 1
8.2.1 Market Estimates & Forecast, 2020-2027
8.3 Diabetes 2
8.3.1 Market Estimates & Forecast, 2020-2027
9. Global Diabetic Nephropathy Market, by End User
9.1 Introduction
9.2 Hospital & Clinics
9.2.1 Market Estimates & Forecast, 2020-2027
9.3 Surgical Centers
9.3.1 Market Estimates & Forecast, 2020-2027
10. Global Diabetic Nephropathy Market, by Region
10.1 Introduction
10.2 Americas
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1 Canada
10.2.2 South America
10.3 Europe
10.3.1 Western Europe
10.3.1.1 Germany
10.3.1.2 France
10.3.1.3 U.K
10.3.1.4 Italy
10.3.1.5 Spain
10.3.1.6 Rest of Western Europe
10.3.2 Eastern Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa
11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments
12 Company Profiles
12.1 Bayer AG
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.2 Merck & Co., Inc.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.3 Novartis AG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.4 Reata Pharmaceuticals, Inc.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.5 Pfizer Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial overview
12.5.4 Key Developments
12.6 Abbott
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Sanofi
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.8 Others
13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Healthcare Diagnostics Industry
14 Appendix
LIST OF TABLES
Table 1 Diabetic Nephropathy Industry Synopsis, 2020-2027
Table 2 Global Diabetic Nephropathy Market Estimates and Forecast, 2020-2027, (USD Million)
Table 3 Global Diabetic Nephropathy Market by Region, 2020-2027, (USD Million)
Table 4 Global Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 5 Global Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 6 Global Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 7 Global Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 8 North America Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 9 North America Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 10 North America Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 11 North America Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 12 US Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 13 US Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 14 US Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 15 US Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 16 Canada Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 17 Canada Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 18 Canada Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 19 Canada Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 20 South America Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 21 South America Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 22 South America Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 23 South America Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 24 Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 25 Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 26 Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 27 Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 28 Western Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 29 Western Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 30 Western Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 31 Western Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 32 Eastern Europe Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 33 Eastern Europe Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 34 Eastern Europe Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 35 Eastern Europe Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 36 Asia Pacific Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 37 Asia Pacific Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 38 Asia Pacific Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 39 Asia Pacific Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
Table 40 Middle East & Africa Diabetic Nephropathy Market by Diagnosis, 2020-2027, (USD Million)
Table 41 Middle East & Africa Diabetic Nephropathy Market by Treatment, 2020-2027, (USD Million)
Table 42 Middle East & Africa Diabetic Nephropathy Market by Indication, 2020-2027, (USD Million)
Table 43 Middle East & Africa Diabetic Nephropathy Market by End Users, 2020-2027, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for Global Diabetic Nephropathy Market
Figure 3 Segmentation Market Dynamics for Diabetic Nephropathy Market
Figure 4 Global Diabetic Nephropathy Market Share, by Treatment 2020
Figure 5 Global Diabetic Nephropathy Market Share, by Indication 2020
Figure 6 Global Diabetic Nephropathy Market Share, by End Users, 2020
Figure 7 Global Diabetic Nephropathy Market Share, by Region, 2020
Figure 8 North America Diabetic Nephropathy Market Share, by Country, 2020
Figure 9 Europe Diabetic Nephropathy Market Share, by Country, 2020
Figure 10 Asia Pacific Diabetic Nephropathy Market Share, by Country, 2020
Figure 11 Middle East & Africa Diabetic Nephropathy Market Share, by Country, 2020
Figure 12 Global Diabetic Nephropathy Market: Company Share Analysis, 2020 (%)
Figure 13 Bayer AG: Key Financials
Figure 14 Bayer AG: Segmental Revenue
Figure 16 Bayer AG: Geographical Revenue
Figure 17 Merck & Co., Inc.: Key Financials
Figure 18 Merck & Co., Inc.: Segmental Revenue
Figure 19 Merck & Co., Inc.: Geographical Revenue
Figure 20 Novartis AG: Key Financials
Figure 21 Novartis AG: Segmental Revenue
Figure 22 Novartis AG: Geographical Revenue
Figure 23 Reata Pharmaceuticals, Inc.: Key Financials
Figure 24 Reata Pharmaceuticals, Inc.: Segmental Revenue
Figure 25 Reata Pharmaceuticals, Inc.: Geographical Revenue
Figure 26 Abbott: Key Financials
Figure 27 Abbott: Segmental Revenue
Figure 28 Abbott: Geographical Revenue
Figure 29 Pfizer Inc.: Key Financials
Figure 30 Pfizer Inc.: Segmental Revenue
Figure 31 Pfizer Inc.: Geographical Revenue
Figure 32 Sanofi: Key Financials
Figure 33 Sanofi: Segmental Revenue
Figure 34 Sanofi: Geographical Revenue
